DJIA 17,598.01 241.14 1.39%
NASDAQ 4,715.41 71.09 1.53%
S&P 500 2,039.26 26.37 1.31%
market minute promo

Rexahn Pharmaceuticals (NYSEMKT: RNN)

0.74 0.01 (1.12%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RNN $0.74 1.12%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.73
Previous Close $0.73
Daily Range $0.73 - $0.74
52-Week Range $0.42 - $1.85
Market Cap $131.6M
P/E Ratio -7.30
Dividend (Yield) $0.00 (0.0%)
Volume 285,701
Average Daily Volume 719,403
Current FY EPS -$0.12

Sector

Healthcare

Industry

Drugs

Rexahn Pharmaceuticals (RNN) Description

Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Website: http://www.rexahn.com/

News & Commentary

This Week in Biotech: NW Bio Soars While Geron Goes Geronimo

Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.

Why Rexahn Pharmaceuticals (RNN) Could Be Positioned for a Surge? - Tale of the Tape

Rexahn Pharmaceuticals (RNN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape

Update: Rexahn Q3 Earnings, Bull Thesis Reiterated

Events for the Week of Nov. 17-21, 2014

Rexahn's New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine And Cisplatin

Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape

Rexahn Update: A Partnership Is All The More Likely

Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% - Tale of the Tape

Rexahn Receives A Notice of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted

Rexahn Receives A Notice of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform

Update: Rexahn Q2 Earnings - Stock Down, But My Optimism Remains Intact

See More RNN News...

RNN's Top Competitors

RNN $0.74 (1.12%)
Current stock: RNN
AMGN $165.72 (1.37%)
Current stock: AMGN
GILD $104.85 (2.39%)
Current stock: GILD
BIIB $344.60 (3.52%)
Current stock: BIIB